(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 October 2007 (25.10.2007)

PCT

(10) International Publication Number
WO 2007/120385 A3

(51) International Patent Classification:
A61K 9/22 (2006.01) *A61K 31/455* (2006.01)

(21) International Application Number:
PCT/US2007/004105

(22) International Filing Date:
15 February 2007 (15.02.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/774,339 17 February 2006 (17.02.2006) US

(71) Applicant *(for all designated States except US)*: **KOS LIFE SCIENCES, INC.**; 2100 North Commerce Parkway, Weston, FL 33326 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ROCCA, Jose, G.** [US/US]; NW 32nd Street 9816, Miami, FL 33172 (US). **ZHU, Yucun** [US/US]; Conservation Drive 506, Weston, FL 33327 (US). **CEFALI, Eugenio, A.** [US/US]; NE 12th Avenue 320, Fort Lauderdale, FL 33301 (US).

(74) Agent: **PROVOOST, Jonathan, N.**; Senior Intellectual Property Counsel, Kos Pharmaceuticals, Inc, 1 Cedar Brook Drive, Cranbury, NJ 08512-3618 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
3 January 2008

[Continued on next page]

(54) Title: LOW FLUSH NIACIN FORMULATION

Mean Niacin Dissolution from Niacin ER 1000mg Tablets Containing Various Levels of METHOCEL® K-15M Premium



(57) Abstract: The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment.

WO 2007/120385 A3

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.